Literature DB >> 25657193

Daptomycin-induced eosinophilic pneumonia treated with intravenous corticosteroids.

Shao-Yu Chiu1, Andrew C Faust2, Hemant M Dand3.   

Abstract

OBJECTIVE: To describe 2 cases of drug-induced eosinophilic pneumonia in patients with variable exposure to daptomycin. REPORT: In our first case, a 77-year-old male was transferred to our facility for hypoxic respiratory failure, which occurred 1 day after completing a course of daptomycin. There was high clinical suspicion for daptomycin-induced eosinophilic pneumonia, thus the patient was started on intravenous methylprednisolone 40 mg every 6 hours. Within 72 hours, he was liberated from mechanical ventilation, as he experienced dramatic clinical improvement in regard to his oxygenation and radiographs. Approximately 6 weeks after case 1, a second case of eosinophilic pneumonia related to daptomycin was diagnosed. This case occurred in a 74-year-old female who developed respiratory failure requiring noninvasive positive pressure ventilation 72 hours after initiation of a second course of daptomycin. She was treated with methylprednisolone 60 mg every 6 hours and avoided the need for endotracheal intubation and mechanical ventilation.
CONCLUSION: Since this potentially life-threatening adverse effect of daptomycin appears more common than previously reported, clinicians should have a high level of suspicion in any patient with recent daptomycin exposure who presents with pulmonary symptoms. In many cases, this process is highly responsive to prompt initiation of corticosteroid therapy.
© The Author(s) 2015.

Entities:  

Keywords:  critical care; infectious disease; pulmonology

Mesh:

Substances:

Year:  2015        PMID: 25657193     DOI: 10.1177/0897190014568678

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  6 in total

Review 1.  Daptomycin-induced eosinophilic pneumonia - a systematic review.

Authors:  Priyasha Uppal; Kerry L LaPlante; Melissa M Gaitanis; Matthew D Jankowich; Kristina E Ward
Journal:  Antimicrob Resist Infect Control       Date:  2016-12-12       Impact factor: 4.887

2.  Two patients with daptomycin induced eosinophilic pneumonia with different presentations and treatment.

Authors:  Yonas Raru; Fuad Zeid; Shannon Browning; Elizabeth Saunders
Journal:  Respir Med Case Rep       Date:  2017-11-13

3.  Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses.

Authors:  Sijan Basnet; Niranjan Tachamo; Rashmi Dhital; Biswaraj Tharu
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

4.  Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature.

Authors:  Yoshitsugu Higashi; Shigeki Nakamura; Yasuhiro Tsuji; Chika Ogami; Kaoru Matsumoto; Koyomi Kawago; Kotaro Tokui; Ryuji Hayashi; Ippei Sakamaki; Yoshihiro Yamamoto
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

5.  Daptomycin eosinophilic pneumonia: an adverse effect to be aware of.

Authors:  G Abelenda Alonso; I Montes Rodríguez; J Martín Torres; P Del Valle Loarte
Journal:  Rev Esp Quimioter       Date:  2018-05-22       Impact factor: 1.553

6.  Meropenem: A possible new culprit in eosinophilic lung diseases.

Authors:  Nathalie Abi Hatem; Sabrina Campbell; Edmundo Rubio; Anthony Lukas Loschner
Journal:  Lung India       Date:  2017 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.